Varian Medical Systems received regulatory clearance in the U.S. and Europe for its VitalBeam radiotherapy platform, netting both 510(k) clearance from the FDA and the CE Mark.

CMS is proposing not to offer lenience on its reimbursement constraints around a sodium-fluoride PET agent, NaF-18, which is used in finding metastasized cancer cells in bones.

A new MRI technique being studied at Memorial Sloan Kettering Cancer Center in New York City could cut the time needed to reveal whether a tumor is responding to treatment from a matter of weeks to just a few days.

Cell-based therapies that exploit modified human cells to treat cancer have been a promising area of research, but issues remain. Specifically, the driver-less cells are difficult to target, especially in tissues deep in the body.

A new Oxford spinout is planning to commercialise titania nanoparticles capable of generating cancer-killing free oxygen radicals in tandem with radiotherapy to treat patients with malignant tumours.

The American Lung Association, currently funding more than $6.49 million in groundbreaking research, continues its investment in lung health research, expecting to offer at least $6.5 million dollars in new grants in fiscal year 2017, including a new research award with a focus on lung cancer in women.

GE Healthcare’s new low-dose screening reference protocols have been cleared by the FDA for lung cancer screening.

With thyroid cancer incidence rates rising at a perplexing rate, concerns about overdiagnosis are starting to take center stage. A paper citing a few reasons for this spike in overdiagnosis, and how radiologists can help stem the tide, was recently published online in Academic Radiology.